Fermentas

US patents awarded to University of California, Hospital for Sick Children, Thermo Fisher, Fujifilm, Abbott, and Novartis.

The deal is expected to bolster Thermo's capabilities in PCR and quantitative real-time PCR.

The acquisition will add reagents for nucleic acid and protein purification, restriction and modifying enzymes, and other life science research and diagnostic tools to Thermo's Analytical Technologies portfolio.

When considering Thermo's planned acquisition of molecular biology tool shop Fermentas, its acquisition earlier this year of Finnish PCR firm Finnzymes, and recent product launches, it appears as if the company plans to make a run at disease diagnostics, food testing, and other PCR-based testing markets.

Thomas Weisel Partners called Thermo Fisher's planned $260 million acquisition of Fermentas a "synergistic tuck-in deal" that "bolsters Thermo's capabilities in the high-growth PCR market."

Based in Ontario with principal operations in Lithuania, Fermentas offers reagents for nucleic acid and protein purification, restriction and modifying enzymes, and various PCR products.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.